Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.71 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 2/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | CTSB | P07858 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24224252 | 1.00 | REN (0.71) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL28611118 | 1.00 | REN (0.71) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL12242944 | 1.00 | REN (0.71) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL18229266 | 1.00 | REN (0.71) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL7269523 | 1.00 | REN (0.71) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL9551232 | 0.99 | REN (0.73) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL5994686 | 0.96 | REN (0.73) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL9101385 | 0.96 | REN (0.73) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL6897460 | 0.96 | REN (0.73) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL3046634 | 0.96 | REN (0.73) | RENCTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118894900-A | Beta carboline oral small-molecule anti-inflammatory medicament as well as preparation method and application thereof | 首都医科大学 | 2024-11-05 | — | — | CN | claimed |
| CN-116804040-B | Carboline oral small molecule anti-inflammatory medicament and preparation method and application thereof | 首都医科大学 | 2024-08-06 | — | — | CN | claimed |
| CN-116804040-A | Carboline oral small molecule anti-inflammatory medicament and preparation method and application thereof | 首都医科大学 | 2023-09-26 | — | — | CN | claimed |
| US-12415819-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-09-16 | — | — | US | disclosed |
| CN-118894900-A | Beta carboline oral small-molecule anti-inflammatory medicament as well as preparation method and application thereof | 首都医科大学 | 2024-11-05 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-116804040-B | Carboline oral small molecule anti-inflammatory medicament and preparation method and application thereof | 首都医科大学 | 2024-08-06 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-117279636-A | Methods and compounds for modulating myotonic muscular dystrophy type 1 | 设计治疗公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-110799193-B | Copper and nickel catalyzed decarboxylation borylation | 斯克利普斯研究院 | 2023-12-12 | — | — | CN | disclosed |
| CN-113831391-B | Dipeptide compound capable of exerting rapid antidepressant effect and application thereof | 南京医科大学 | 2023-10-13 | — | — | CN | disclosed |
| EP-0296581-A2 | Amino acid 1,2-diketo derivatives as renin inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1988-12-28 | — | — | EP | disclosed |
| US-4657931-A | RENIN-INHIBITING | G. D. SEARLE & CO. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4642315-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1987-02-10 | — | — | US | disclosed |
| EP-0202577-A2 | N(Acyldipeptidyl)-aminoglycols | G.D. Searle & Co. (US) | 1986-11-26 | — | — | EP | disclosed |
| US-4587234-A | HYPOTENSIVES | E. R. SQUIBB & SONS, INC. (US) | 1986-05-06 | — | — | US | disclosed |
| US-4499079-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
| US-4465668-A | CONTAINING A BONDED OLIGOPEPTIDE GROUP | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-08-14 | — | — | US | disclosed |
| US-4432972-A | HYPOTENSIVE AGENTS, KANALGESICS, AND ANGIOTENSIN AND ENKEPHALIN INHIBITION | E. R. SQUIBB & SONS, INC. (US) | 1984-02-21 | — | — | US | disclosed |
| EP-0060422-A2 | Method for improving intestinal absorption of cephalosporin derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415819-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | PCSK9, PCSK7, PCSK6 | REN 100/4885CTSS 309/4885CTSK 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.